Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

v3.22.0.1
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 03, 2021
Jul. 19, 2021
Jun. 19, 2021
Jun. 19, 2021
Jun. 18, 2021
Jul. 02, 2020
Jan. 14, 2020
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Jun. 19, 2020
Jun. 19, 2018
Subsidiary, Sale of Stock [Line Items]                        
Net proceeds from public offering of common stock             $ 50,000,000.0   $ 5,580,471 $ 46,704,210    
Research and Development Expense                 $ 14,583,283 $ 14,358,918    
Net proceeds from public offering of common stock             $ 46,700,000          
Preferred stock shares authorized                 8,000 8,000    
Preferred stock par value                 $ 1,000 $ 1,000    
Preferred stock, shares outstanding                 0 4,361    
Common stock, shares outstanding                 216,269,450 200,113,431    
Number of warrant to purchase of common stock                 988,000      
Maximum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of warrant or right, exercise price of warrants or rights                 $ 0.50      
Minimum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of warrant or right, exercise price of warrants or rights                 $ 0.75      
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Share price             $ 1.55          
Issuance of common stock in public offering, shares             32,260,000   3,023,147 32,260,000    
Shares converted   2,000                    
Shares issued upon conversion   8,436,000                    
Series A Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                 10,000,000      
Preferred stock par value                 $ 0.001      
Series A Preferred Stock [Member] | Designated [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                 1,600,000      
Series B Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                       8,000
Shares converted     4,218   143       143      
Preferred stock, shares outstanding                 4,361 0    
Liquidity value and dividends description                 (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling 1,687,200 and 1,365,600 shares of common stock, respectively      
Common stock, shares outstanding     1,687,200 1,687,200             1,365,600  
Series B Preferred Stock [Member] | Holders [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of preferred stock shares converted       8,436,000                
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Shares converted         286,000       286,000      
Aquarius Merger Agreement [Member] | Holders Of Aquarius Biotechnologies Inc [Member] | Unregistered Shares [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Business acquisition, equity iterest issued or issuable, shares 1,500,000                      
Research and Development Expense $ 1,200,000                      
Share price $ 0.80                      
Conversion price per share     $ 0.50 $ 0.50                
Underwritten Public Offering [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Net proceeds from public offering of common stock             $ 50,000,000.0          
Net proceeds from public offering of common stock             $ 46,700,000          
Underwritten Public Offering [Member] | Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Issuance of common stock in public offering, shares             32,600,000          
Underwritten Public Offering [Member] | Sales Agreement [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Aggregate offering price for sale of stock           $ 50,000,000            
Sale of stock percentage           3.00%            
Sale of stock shares               3,023,147        
Proceeds from issuance of common stock               $ 5,800,000        
Net proceeds from public offering of common stock               $ 5,600,000